<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ | æå®¢å¿«è¨Š</title><meta property="og:title" content="æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ - æå®¢å¿«è¨Š"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p1.pstatp.com/large/pgc-image/de56ebe768384fb9b518ba6ba5678b7a"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/4b93cacb.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/4b93cacb.html><meta property="article:published_time" content="2020-11-14T21:02:06+08:00"><meta property="article:modified_time" content="2020-11-14T21:02:06+08:00"><meta name=Keywords content><meta name=description content="æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ"><meta name=author content="æå®¢å¿«è¨Š"><meta property="og:url" content="/cn/%E7%A7%91%E6%8A%80/4b93cacb.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>ğŸ¤“ æå®¢å¿«è®¯ Geek Bank</a></h1><p class=description>ä¸ºä½ å¸¦æ¥æœ€å…¨çš„ç§‘æŠ€çŸ¥è¯† ğŸ§¡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>çŒœä½ å–œæ­¡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=ç§‘æŠ€>ç§‘æŠ€</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=éŠæˆ²>éŠæˆ²</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=ç§‘å­¸>ç§‘å­¸</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E6%8A%80.html>ç§‘æŠ€</a></span></div><div class=post-content><blockquote class=pgc-blockquote-abstract><p>æœ¬æ–‡ä½œè€…ï¼šå¼ åº·å¹³ï¼Œå¼ çªï¼Œäºæºè‹±ï¼Œé™ˆæ°¸å…µï¼Œé¥¶æœ¬å¼ºï¼ŒçŸ³æ±‰å¹³ ï¼ˆé¦–éƒ½åŒ»ç§‘å¤§å­¦é™„å±åŒ—äº¬ä¸–çºªå›åŒ»é™¢â€ƒèƒƒè‚ å¤–ç§‘ï¼ŒåŒ—äº¬â€ƒ100038ï¼‰</p><p>PDFä¸‹è½½é“¾æ¥ï¼š</p><p>http://www.yixueqianyan.cn/CN/abstract/abstract3190.shtml</p></blockquote><blockquote class=pgc-blockquote-abstract><p>ã€æ‘˜è¦ã€‘â€ƒå²å“šèƒº2,3-åŒåŠ æ°§é…¶ï¼ˆindoleamine 2,3-dioxygenaseï¼ŒIDOï¼‰ä¸ä»…æ˜¯å¯åŠ¨è‰²æ°¨é…¸åˆ†è§£ä»£è°¢çš„å…³é”®é…¶ï¼Œä¹Ÿæ˜¯ä¸€ç§ä¸æœºä½“å¤–å‘¨å…ç–«è€å—ç°è±¡å’Œæœºä½“å…ç–«æŠ‘åˆ¶ä½œç”¨ç›¸å…³çš„å…ç–«è°ƒèŠ‚é…¶ã€‚IDOä½œä¸ºä¸€ç§å…ç–«æŠ‘åˆ¶åˆ†å­ï¼Œåœ¨å¤šç§æ¶æ€§è‚¿ç˜¤ç»„ç»‡ä¸­é«˜è¡¨è¾¾ï¼Œå¹¶ä¸ä¸è‰¯é¢„åå¯†åˆ‡ç›¸å…³ï¼Œå› æ­¤æœ‰æ•ˆæŠ‘åˆ¶IDOæ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ã€‚å°†IDOæŠ‘åˆ¶å‰‚ä¸æ‰‹æœ¯ã€åŒ–ç–—ã€æ”¾ç–—ç­‰è¿›è¡Œè”åˆæ²»ç–—ï¼Œæ˜¯è¿‘å¹´æ¥ä¸æ–­è¢«æ¢ç©¶ä¸”å‰æ™¯è‰¯å¥½çš„è‚¿ç˜¤æ²»ç–—æ–¹å‘ã€‚IDOæŠ‘åˆ¶å‰‚ç§ç±»ä¸»è¦åŒ…æ‹¬ï¼š1-ç”²åŸº-DL-è‰²æ°¨é…¸ï¼ˆ1-methyl-DL-tryptophanï¼Œ1-MTï¼‰å’Œepacadostatä¸ºä»£è¡¨çš„ç«äº‰æ€§æŠ‘åˆ¶å‰‚ï¼Œnavoximodä¸ºä»£è¡¨çš„éç«äº‰æ€§æŠ‘åˆ¶å‰‚ï¼Œä»¥åŠBMS-986205ã€exiguamine Aç­‰å…¶ä»–ç§ç±»çš„æŠ‘åˆ¶å‰‚ã€‚IDOæŠ‘åˆ¶å‰‚ç§ç±»ç¹å¤šï¼Œä½†è¿›å…¥ä¸´åºŠè¯•éªŒé˜¶æ®µçš„è¾ƒå°‘ï¼Œæœ¬æ–‡ä¸»è¦é’ˆå¯¹indoximodã€epacadostatã€navoximodã€BMS-986205å’ŒHTI-1090ç­‰IDOæŠ‘åˆ¶å‰‚çš„ä¸´åºŠç ”ç©¶ç°çŠ¶è¿›è¡Œé˜è¿°ã€‚</p><p>ã€å…³é”®è¯ã€‘â€ƒå²å“šèƒº2,3-åŒåŠ æ°§é…¶ï¼›è‚¿ç˜¤ï¼›å²å“šèƒº2,3-åŒåŠ æ°§é…¶æŠ‘åˆ¶å‰‚</p></blockquote><p><br></p><p>å…ç–«æ²»ç–—ä»æ˜¯è‚¿ç˜¤æ²»ç–—çš„æ´»è·ƒé¢†åŸŸï¼Œéšç€äººä»¬å¯¹è‚¿ç˜¤å¾®ç¯å¢ƒã€è‚¿ç˜¤å…ç–«é€ƒé€¸å’Œè‚¿ç˜¤å…ç–«è€å—ç­‰ç°è±¡è®¤è¯†çš„é€æ­¥æ·±å…¥ï¼Œå¤‡å—ç©ç›®çš„è‚¿ç˜¤å…ç–«æ²»ç–—å·²åœ¨å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚æ–¹é¢å–å¾—çªç ´æ€§è¿›å±•ï¼Œç‰¹åˆ«æ˜¯ç¨‹åºæ€§æ­»äº¡è›‹ç™½-1ï¼ˆprogrammed death protein-1ï¼ŒPD-1ï¼‰/ç¨‹åºæ€§æ­»äº¡è›‹ç™½é…ä½“-1ï¼ˆprogrammed death ligÂ­aÂ­nd-1ï¼ŒPD-L1ï¼‰æŠ‘åˆ¶å‰‚ã€ç»†èƒæ¯’Tæ·‹å·´ç»†èƒç›¸å…³æŠ—åŸ4ï¼ˆcytotoxic T lymphocyte-associated antigen-4ï¼ŒCTLA-4ï¼‰æŠ‘åˆ¶å‰‚ç­‰ï¼Œä¸ºå…ç–«ç–—æ³•è°±å†™äº†å´­æ–°ç¯‡ç« ã€‚å²å“šèƒº2,3-åŒåŠ æ°§é…¶ï¼ˆindoleamine 2ï¼Œ3-dioxygenaseï¼ŒIDOï¼‰ä½œä¸ºä¸€ç§æŠ‘åˆ¶æ€§å…ç–«æ£€æŸ¥ç‚¹ï¼Œè¢«å‘ç°åœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­å‘æŒ¥ç€é‡è¦è°ƒèŠ‚ä½œç”¨ï¼Œå·²æˆä¸ºè‚¿ç˜¤å…ç–«æ²»ç–—ä¸­é‡è¦çš„ç ”ç©¶ç›®æ ‡ã€‚</p><h1 class=pgc-h-arrow-right>1â€ƒIDOè¡¨è¾¾ä¸è°ƒèŠ‚</h1><p>IDOæ˜¯L-è‰²æ°¨é…¸ï¼ˆL-tryptophanï¼ŒL-Trpï¼‰åˆ†è§£ä»£è°¢ä¸»è¦é€”å¾„ä¸­çš„å…³é”®é™é€Ÿé…¶ï¼Œå¯å‚¬åŒ–L-è‰²æ°¨é…¸æ²¿çŠ¬å°¿æ°¨é…¸é€”å¾„ä»£è°¢ç”ŸæˆçŠ¬å°¿æ°¨é…¸åŠå…¶å¤šç§è¡ç”Ÿç‰©ï¼Œå¦‚å¯ç»´æŒç»†èƒç¨³æ€çš„çƒŸé…°èƒºè…ºå˜Œå‘¤äºŒæ ¸è‹·é…¸[1,2]ã€‚IDOåŒæ—¶ä¹Ÿæ˜¯ä¸€ç§é‡è¦çš„å…ç–«è°ƒèŠ‚é…¶[3]ï¼Œå…¶é€šè¿‡ç”Ÿæˆçš„ä»£è°¢äº§ç‰©è°ƒèŠ‚æœºä½“å…ç–«ç³»ç»Ÿï¼Œå‘æŒ¥å…ç–«è°ƒèŠ‚ä½œç”¨ã€‚IDOæ˜¯ç”±äººç±»ç¬¬8å·æŸ“è‰²ä½“ä¸Šçš„INDOåŸºå› ç¼–ç çš„ç»†èƒå†…å«é“è¡€çº¢ç´ é…¶ï¼Œå«æœ‰403ä¸ªæ°¨åŸºé…¸ï¼Œæ€»åˆ†å­é‡çº¦ä¸º42 kDa[4]ã€‚IDOåŒ…æ‹¬å²å“šèƒº2,3-åŒåŠ æ°§é…¶1ï¼ˆindoleamine 2,3-dioxygenase 1ï¼ŒIDO1ï¼‰å’Œå²å“šèƒº2,3-åŒåŠ æ°§é…¶ 2ï¼ˆindoleamine 2,3-dioxygenase 2ï¼ŒIDO2ï¼‰ï¼Œå…¶ä¸­IDO2çš„è°ƒæ§ä½œç”¨ä¸IDO1å¹¶ä¸å®Œå…¨ä¸€è‡´ã€‚åœ¨æ­£å¸¸äººä½“ä¸­ï¼ŒIDOä¸»è¦åœ¨å°è‚ ã€å¥³æ€§ç”Ÿæ®–é“å’Œèƒç›˜ç­‰éƒ¨ä½å‘ˆä½è¡¨è¾¾[5,6]ã€‚ç ”ç©¶è¡¨æ˜ï¼ŒIDOåœ¨è‚ºç™Œ[7]ã€é»‘è‰²ç´ ç˜¤[8]ã€ä¹³è…ºç™Œ[9]ã€åµå·¢ç™Œ[10]ã€é»˜å…‹å°”ç»†èƒç™Œ[11]å’Œç»“è‚ ç™Œ[12]ç­‰å¤šç§æ¶æ€§è‚¿ç˜¤æ‚£è€…ä½“å†…æ´»æ€§å¢å¼ºï¼Œå‘ˆé«˜è¡¨è¾¾çŠ¶æ€ï¼Œä¸”IDOé«˜è¡¨è¾¾ä¸é¢„åè¾ƒå·®æœ‰å…³ã€‚ç ”ç©¶è¡¨æ˜ï¼ŒIDOæ˜¯å¯¼è‡´äººä½“å†…å¤–å‘¨å…ç–«è€å—çš„ä¸€ç§å†…æºæ€§æœºåˆ¶[13]ï¼Œä¹Ÿæ˜¯è‚¿ç˜¤å…ç–«æ²»ç–—ä¸­é‡è¦çš„è°ƒæ§é¶ç‚¹[14]ï¼Œä¸ä¿ƒè¿›è‚¿ç˜¤å…ç–«è€å—ã€è‚¿ç˜¤å‘å±•å’Œæ¶æ€§è‚¿ç˜¤ä¸è‰¯é¢„åå¯†åˆ‡ç›¸å…³[15-17]ã€‚å› æ­¤ï¼ŒIDOè¢«è®¤ä¸ºæ˜¯ä¸€ä¸ªèƒ½å¤Ÿå¢å¼ºè‚¿ç˜¤å…ç–«æ²»ç–—æ•ˆæœçš„æ–°é¶ç‚¹ã€‚åœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­ï¼ŒIDOé€šè¿‡è€—ç«­å±€éƒ¨å¾®ç¯å¢ƒä¸­çš„è‰²æ°¨é…¸ï¼Œè¿›è€ŒæŠ‘åˆ¶ä¸/è‹æ°¨é…¸è›‹ç™½æ¿€é…¶â€”â€”å“ºä¹³åŠ¨ç‰©é›·å¸•éœ‰ç´ é¶è›‹ç™½æ•æ„Ÿå‹å¤åˆä½“1ï¼ˆmammalian target of rapaÂ­mÂ­ycin complex 1ï¼ŒmTORC1ï¼‰ï¼Œè‡´ä½¿Tæ·‹å·´ç»†èƒåŠŸèƒ½ä¸§å¤±ï¼›ä¹Ÿå¯é€šè¿‡æ¿€æ´»ä¸€èˆ¬æ€§è°ƒæ§é˜»éè›‹ç™½æ¿€é…¶2ï¼ˆgeneral control nonderepressible 2 kinaseï¼ŒGCN2ï¼‰ï¼Œå¯¼è‡´æ•ˆåº”Tç»†èƒå¢æ®–å‡å°‘[18,19]ã€‚æ­¤å¤–ï¼ŒIDOå‚¬åŒ–è‰²æ°¨é…¸åˆ†è§£äº§ç”Ÿçš„ä»£è°¢äº§ç‰©å¯ä»¥æ¿€æ´»èŠ³é¦™çƒƒå—ä½“AhRï¼ŒæŠ‘åˆ¶Tç»†èƒå¢æ®–[20,21]ã€‚IDOè¿˜å¯ä»¥è¯±å¯¼è°ƒèŠ‚æ€§Tç»†èƒæ‰©å¢ï¼Œæ¿€æ´»è°ƒèŠ‚æ€§Tç»†èƒçš„å…ç–«æŠ‘åˆ¶åŠŸèƒ½[22,23]ã€‚åœ¨ä¸Šè¿°ä»£è°¢é€šè·¯ä¸­ï¼ŒIDOæŠ‘åˆ¶å‰‚ä¸»è¦é€šè¿‡ä¸è‰²æ°¨é…¸ç«äº‰æ€§ç»“åˆIDOçš„å‚¬åŒ–ç»“æ„åŸŸæˆ–éç«äº‰çš„æœºåˆ¶æ¥å½±å“è‰²æ°¨é…¸çš„ä»£è°¢ï¼Œè¿›è€Œå‘æŒ¥å¯¹IDOçš„æŠ‘åˆ¶ä½œç”¨ï¼ˆå›¾1ï¼‰ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/de56ebe768384fb9b518ba6ba5678b7a><p class=pgc-img-caption></p></div><h1 class=pgc-h-arrow-right>2â€ƒIDOæŠ‘åˆ¶å‰‚ä¸´åºŠå‘å±•ç°çŠ¶</h1><p>å½“å‰æŠ¥é“çš„å¤§å¤šæ•°IDOæŠ‘åˆ¶å‰‚ä»å°šæœªè¿›å…¥ä¸´åºŠè¯•éªŒé˜¶æ®µï¼Œå·²ç»è¿›å…¥ä¸´åºŠè¯•éªŒé˜¶æ®µçš„ä¸»è¦åŒ…æ‹¬indoximodï¼ˆ1-D-MTï¼Œå²å“šè«å¾·ï¼ŒNLG-8189ï¼‰ã€epacaÂ­dostatï¼ˆINCB024360ï¼‰ã€navoximodå’ŒBMS-986205ç­‰ã€‚ä»¥ä¸‹ä¸»è¦ä»‹ç»6ç§IDOæŠ‘åˆ¶å‰‚å•ä¸€æˆ–è”åˆç”¨è¯çš„ä¸´åºŠç ”ç©¶ç°çŠ¶ã€‚è¡¨1æ±‡æ€»äº†ä¸»è¦è®¨è®ºçš„6ç§IDOæŠ‘åˆ¶å‰‚ç›®å‰å…·æœ‰ä»£è¡¨æ€§çš„ä¸´åºŠè¯•éªŒä¿¡æ¯ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/933daf5b854e412e9ac7acb63a04dec7><p class=pgc-img-caption></p></div><p><br></p><p><strong>2.1â€ƒindoximodâ€ƒ</strong>åˆç§°1-D-MTï¼Œå²å“šè«å¾·ï¼ŒNLG-8189ï¼Œæ˜¯ç”±NewLink Geneticsï¼ˆNLNKï¼‰å…¬å¸ç ”å‘çš„æœ€å…·ä»£è¡¨æ€§çš„è‰²æ°¨é…¸ç±»ä¼¼ç‰©æŠ‘åˆ¶å‰‚ï¼ˆç»“æ„å¼è§å›¾2ï¼‰ã€‚1-MTæœ‰2ç§ç«‹ä½“å¼‚æ„ä½“ï¼Œå³å·¦æ—‹ä½“1-L-MTä¸å³æ—‹ä½“1-D-MTï¼ˆindoximodï¼‰ã€‚è‰²æ°¨é…¸æ¶ˆè€—å°†å¯¼è‡´mTORC1ä¿¡å·é€šè·¯å—åˆ°æŠ‘åˆ¶ï¼Œindoximodèƒ½å¤Ÿå‡è½»è¯¥æŠ‘åˆ¶ä½œç”¨ï¼Œæ¢å¤mTORC1çš„æ´»æ€§ï¼Œå› æ­¤indoximodå¹¶éä½œç”¨äºIDOæœ¬èº«ï¼Œè€Œæ˜¯é—´æ¥å‘æŒ¥æŠ‘åˆ¶ä½œç”¨[18,25]ã€‚indoximodå•è¯æˆ–è”åˆåŒ–ç–—ï¼ˆindoximodä¸å¤šè¥¿ä»–èµ›è”åˆï¼‰æ²»ç–—æ™šæœŸä¹³è…ºç™Œæˆ–å…¶ä»–å®ä½“ç˜¤çš„â… æœŸä¸´åºŠè¯•éªŒç»“æœè¡¨æ˜ï¼Œæ‚£è€…å¯¹å…¶è€å—æ€§è‰¯å¥½[26,27]ã€‚ä¸€é¡¹â… æœŸä¸´åºŠè¯•éªŒï¼ˆNCT00567931ï¼‰è§‚å¯Ÿäº†æ™šæœŸæ¶æ€§è‚¿ç˜¤æ‚£è€…å•ç‹¬åº”ç”¨indoximodæ²»ç–—çš„æœ€å¤§è€å—å‰‚é‡å’Œæ¯’æ€§ï¼Œå½“è¯ç‰©å‰‚é‡è¾¾2000 mgï¼Œæ¯æ—¥2æ¬¡ï¼Œç»™è¯å2.9 hæ—¶è¾¾æœ€å¤§è¡€è¯æµ“åº¦ï¼Œçº¦ä¸º12 Î¼mol/Lï¼Œè¯ç‰©åŠè¡°æœŸä¸º10.5 hï¼Œå—è¯•çš„48ä¾‹æ‚£è€…ä¸­ï¼Œ5ä¾‹æ‚£è€…ç—…æƒ…ç¨³å®šè¶…è¿‡6ä¸ªæœˆ[27,28]ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/62ea7034c91b4593acb27337d0b7caa5><p class=pgc-img-caption></p></div><p>æç¤ºindoximodå…·æœ‰è‰¯å¥½çš„å£æœç”Ÿç‰©åˆ©ç”¨ç‡ã€å®‰å…¨æ€§å’Œè€å—æ€§ã€‚ä½†æœ‰ç ”ç©¶æŒ‡å‡ºï¼Œindoximodå•è¯å‡ ä¹æ²¡æœ‰å‘æŒ¥æŠ—è‚¿ç˜¤ä½œç”¨ï¼Œè€Œä¸å…¶ä»–æ²»ç–—æ–¹æ³•è”åˆä½¿ç”¨æ—¶ç–—æ•ˆæ˜¾è‘—å¢å¼º[13]ã€‚ä¸€é¡¹é’ˆå¯¹è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œçš„éšæœºç ”ç©¶ï¼ˆNCT01560923ï¼‰ä¸­ï¼Œ46ä¾‹åº”ç”¨æ ‘çªçŠ¶ç»†èƒç–«è‹—å…ç–«ç–—æ³•æ²»ç–—çš„æ‚£è€…è¢«åˆ†ä¸ºå®‰æ…°å‰‚ç»„ï¼ˆ24ä¾‹ï¼‰å’Œindoximodç»„ï¼ˆ22ä¾‹ï¼‰ï¼Œç»“æœæ˜¾ç¤ºindoximodç»„æ‚£è€…æ€»ç”Ÿå­˜æœŸå»¶é•¿è¶…è¿‡2å€ï¼Œä¸”æ‚£è€…å¯¹è¯¥è¯ç‰©çš„è€å—æ€§è‰¯å¥½ï¼Œä¸¤ç»„æ‚£è€…çš„ä¸è‰¯ååº”æ— æ˜¾è‘—å·®å¼‚[29]ã€‚ç›®å‰IDOæŠ‘åˆ¶å‰‚ä¸åŒ–ç–—ã€æ”¾ç–—è”åˆæ²»ç–—çš„è¯•éªŒç»“æœå–œå¿§å‚åŠï¼Œæœ‰å¤šé¡¹æ³¨å†Œç ”ç©¶ä»åœ¨ç»§ç»­æ¢ç©¶IDOçš„è”åˆæ²»ç–—æ–¹æ¡ˆï¼ˆå¦‚NCT01792050ï¼ŒNCT02052648ï¼ŒNCT02077881ï¼ŒNCT02502708ï¼ŒNCT02835729ï¼‰ã€‚æ€»æ‹¬è€Œè¨€ï¼Œindoximodæ˜¯ä¸€ç§å…·æœ‰å¹¿æ³›æ½œåœ¨ç”¨é€”çš„é‡è¦çš„IDOæŠ‘åˆ¶å‰‚ï¼Œå…¶å®‰å…¨æ€§è¾ƒå¥½ï¼Œå¹¶æœ‰æœ›æ”¹å–„è‚¿ç˜¤æ²»ç–—ç°çŠ¶[17]ï¼Œä½†è”åˆæ²»ç–—çš„æ–¹æ¡ˆåº”ç»§ç»­è¿›è¡Œè¯•éªŒéªŒè¯ã€‚â€ƒ</p><p><strong>2.2â€ƒepacadostatâ€ƒ</strong>åˆåINCB024360ï¼Œæ˜¯ç”±Incyteå…¬å¸ç ”å‘çš„N-ç¾ŸåŸºè„’ç±»å…·æœ‰é«˜åº¦é€‰æ‹©æ€§çš„IDOæŠ‘åˆ¶å‰‚ï¼Œè¯¥æŠ‘åˆ¶å‰‚æ˜¯ç›®å‰å¼€å±•ç ”ç©¶æœ€å¿«ã€æœ€æ·±å…¥çš„ä¸€ç§é«˜æ•ˆè‰²æ°¨é…¸ç«äº‰æ€§IDOæŠ‘åˆ¶å‰‚ï¼ˆç»“æ„å¼è§å›¾3ï¼‰ã€‚epacadostatå¯ä¸çŠ¬å°¿æ°¨é…¸çš„åº•ç‰©è‰²æ°¨é…¸ç«äº‰ç»“åˆIDOçš„å‚¬åŒ–ç»“æ„åŸŸï¼Œå‘æŒ¥ç«äº‰æ€§æŠ‘åˆ¶IDOçš„ä½œç”¨ï¼Œä»è€Œæœ‰æ•ˆå¹²é¢„è‰²æ°¨é…¸ä»£è°¢è¿‡ç¨‹ï¼Œä½¿å¾—æ•ˆåº”Tç»†èƒå’Œè‡ªç„¶æ€ä¼¤ç»†èƒçš„å¢æ®–å¢å¼ºã€å‡‹äº¡å‡å°‘å’ŒCD86+æ ‘çªçŠ¶ç»†èƒæ´»åŒ–å¢åŠ ï¼ŒåŒæ—¶æŠ‘åˆ¶è°ƒèŠ‚æ€§Tç»†èƒçš„æ‰©å¢[30]ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/ee5e451e097b41a5ab25939bd2ad7952><p class=pgc-img-caption></p></div><p><br></p><p>epacadostatä¸»è¦ç”¨äºåµå·¢ç™Œã€é»‘è‰²ç´ ç˜¤ã€éª¨é«“å¢ç”Ÿå¼‚å¸¸ç»¼åˆå¾ç­‰çš„æ²»ç–—ã€‚ç ”ç©¶æ˜¾ç¤ºï¼Œepacadostatåœ¨ç»†èƒå†…æŠ‘åˆ¶IDO1çš„åŠæ•°æœ‰æ•ˆæµ“åº¦å¯¹IDO2å’Œè‰²æ°¨é…¸2,3-åŒåŠ æ°§é…¶ï¼ˆtryptophan 2,3-dioxygenaseï¼ŒTDOï¼‰çš„æŠ‘åˆ¶ä½œç”¨å¾ˆå¼±ï¼Œè¯æ˜å…¶å¯¹IDO1ä½œç”¨ç‰¹å¼‚æ€§è¾ƒå¼º[31]ã€‚NCT01195311ç ”ç©¶ä¸ºepacadostatçš„â… æœŸä¸´åºŠå‰‚é‡é€’å¢è¯•éªŒï¼Œ52ä¾‹æ™šæœŸæ¶æ€§å®ä½“ç˜¤æ‚£è€…æœç”¨è¯¥è¯æ²»ç–—ï¼Œå‰‚é‡ä¸º50 mgæ¯æ—¥1æ¬¡æˆ–50ã€100ã€300ã€400ã€500ã€600æˆ–700 mgæ¯æ—¥2æ¬¡ï¼Œå¹¶åœ¨ä¸ºæœŸ28 dçš„æ²»ç–—å‘¨æœŸå†…è¿›è¡Œè¯„ä¼°ï¼Œç»“æœæ˜¾ç¤º7ä¾‹æ‚£è€…ç—…æƒ…ç¨³å®šæŒç»­16å‘¨ï¼ˆ112 dï¼‰ä»¥ä¸Šï¼Œæç¤ºepacadostatè€å—æ€§è‰¯å¥½[32]ã€‚</p><p>ä¸ºäº†æ¢ç©¶epacadostatçš„å®‰å…¨æ€§å’Œç»™è¯æ–¹æ¡ˆï¼Œç ”å‘è€…åç»­å¼€å±•äº†å¤šé¡¹â…¡æœŸä¸´åºŠè¯•éªŒã€‚åœ¨éšæœºåŒç›²çš„ECHO-301è¯•éªŒä¸­[33-35]ï¼Œepacadostatä¸å¸•åšåˆ©ç å•æŠ—è”åˆç”¨äºæ²»ç–—è½¬ç§»æ€§é»‘è‰²ç´ ç˜¤çš„â…¡æœŸä¸´åºŠè¯•éªŒç»“æœå¹¶ä¸ç†æƒ³ï¼Œè¯¥ç»„åˆæœªæ”¹å–„ä¸­ä½æ— è¿›å±•ç”Ÿå­˜æœŸçš„ä¸»è¦ç»ˆç‚¹ï¼Œæ€»ç”Ÿå­˜æœŸä¹Ÿæ— æ˜¾è‘—å·®å¼‚ï¼Œè‡´ä½¿ç ”ç©¶æå‰ç»ˆæ­¢[34]ã€‚åœ¨è½¬ç§»æ€§é»‘è‰²ç´ ç˜¤æ‚£è€…çš„â…¢æœŸéšæœºåŒç›²è¯•éªŒï¼ˆECHO-301/KEYNOTE-252ï¼‰ä¸­ï¼Œä¸å®‰æ…°å‰‚ï¼‹å¸•åšåˆ©ç å•æŠ—ç»„ç›¸æ¯”ï¼Œepacadostatï¼ˆ100 mgï¼Œæ¯æ—¥2æ¬¡ï¼‰ï¼‹å¸•åšåˆ©ç å•æŠ—å¹¶ä¸èƒ½æ”¹å–„æ— è¿›å±•ç”Ÿå­˜æœŸæˆ–æ€»ç”Ÿå­˜æœŸï¼Œè®¤ä¸ºé€šè¿‡æŠ‘åˆ¶IDOä½œä¸ºå¢å¼ºæŠ—PD-1æ²»ç–—æ´»æ€§çš„æ–¹æ¡ˆçš„æœ‰æ•ˆæ€§ä»ç„¶ä¸ç¡®å®š[33]ã€‚</p><p>ä½†åœ¨epacadostatä¸å¸•åšåˆ©ç å•æŠ—è”åˆä½¿ç”¨çš„â… æœŸä¸´åºŠè¯•éªŒä¸­ï¼Œå…±çº³å…¥62ä¾‹â…¢BæœŸã€â…£æœŸæˆ–å¤å‘æ€§è‚¿ç˜¤ï¼ˆåŒ…æ‹¬éå°ç»†èƒè‚ºç™Œã€é»‘è‰²ç´ ç˜¤ç­‰ï¼‰æ‚£è€…ï¼Œ8ä¾‹æ‚£è€…è¾¾åˆ°å®Œå…¨ç¼“è§£çš„æœ€ä½³ç»“æœï¼Œ17ä¾‹æ‚£è€…å®ç°äº†éƒ¨åˆ†ç¼“è§£ï¼Œ15ä¾‹æ‚£è€…å‡ºç°å®¢è§‚ååº”ã€‚84%çš„æ‚£è€…å‡ºç°æ²»ç–—ç›¸å…³ä¸è‰¯ååº”ï¼Œä¸»è¦ä¸ºç–²åŠ³ã€çš®ç–¹ç­‰ï¼Œ24%çš„æ‚£è€…å‡ºç°äº†3ï½4çº§ä¸è‰¯ååº”[36]ã€‚æ€»ä½“æ¥çœ‹ï¼Œepacadostatè”åˆå¸•åšåˆ©ç å•æŠ—åœ¨ä¸€äº›è¯•éªŒä¸­è¡¨ç°å‡ºè‰¯å¥½çš„è€å—æ€§ï¼Œä¸”åœ¨æ™šæœŸå®ä½“ç˜¤ä¸­æœ‰æŠ—è‚¿ç˜¤ä½œç”¨[36]ã€‚å³ä½¿epacadostatåœ¨â… /â…¡æœŸä¸´åºŠè¯•éªŒä¸­å…·æœ‰è‰¯å¥½ç»“æœï¼Œä½†å…¶æœªæ¥èƒ½å¦åœ¨â…¢æœŸä¸´åºŠè¯•éªŒä¸­è·å¾—ç†æƒ³ç»“æœï¼Œè¿˜éœ€ç­‰å¾…æ­£åœ¨è¿›è¡Œä¸­çš„ä¸´åºŠè¯•éªŒå‘å¸ƒç»“æœå¹¶å¯¹å…¶è¿›è¡Œç»¼åˆè¯„ä»·ã€‚</p><p><strong>2.3â€ƒnavoximodâ€ƒ</strong>åˆåGDC-0919ï¼ŒNLG-919ï¼Œæ˜¯ç”±NewLink Geneticså…¬å¸ç ”å‘çš„ä¸€ç§æ´»æ€§è¾ƒå¥½çš„éç«äº‰æ€§IDOæŠ‘åˆ¶å‰‚ï¼Œå«æœ‰è‰²æ°¨é…¸IDOæŠ‘åˆ¶å‰‚çš„4-è‹¯åŸºå’ªå”‘ç»“æ„ï¼Œå…¶è¾ƒepacadostatå’ŒBMS-986205å…·æœ‰æ›´å¼ºçš„æŠ—IDOæ´»æ€§ï¼ˆç»“æ„å¼è§å›¾4ï¼‰ã€‚navoximodç›®å‰å¤„äºâ… æœŸä¸´åºŠç ”ç©¶é˜¶æ®µï¼Œåº”ç”¨äºå¤å‘æ€§å®ä½“ç˜¤çš„æ²»ç–—ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/5c7efefeca444a0eb30665fbb4877eee><p class=pgc-img-caption></p></div><p><br></p><p>Maç­‰[37]ç ”ç©¶å‘ç°ï¼Œnavoximodå¸æ”¶è¿…é€Ÿå¹¶ä¸”å…·æœ‰è‰¯å¥½çš„è€å—æ€§ã€‚ä¸€é¡¹é’ˆå¯¹å¤å‘æ€§æ™šæœŸå®ä½“ç˜¤æ‚£è€…çš„â… æœŸä¸´åºŠç ”ç©¶ç»“æœæ˜¾ç¤ºï¼Œnavoximodåœ¨é«˜è¾¾800 mgã€æ¯æ—¥2æ¬¡çš„å‰‚é‡ä¸‹ä»å…·æœ‰è‰¯å¥½çš„è€å—æ€§ï¼Œèƒ½æœ‰æ•ˆé™ä½è¡€æµ†çŠ¬å°¿æ°¨é…¸æ°´å¹³ï¼Œå¹¶ä¸”è§‚å¯Ÿåˆ°ç–¾ç—…ç¨³å®š[38]ã€‚ç„¶è€Œï¼Œ2017å¹´ç¾å›½ä¸´åºŠè‚¿ç˜¤å­¦ä¼šå¹´ä¼šæ‰€å…¬å¸ƒçš„navoximodè”åˆç´«æ‰é†‡æ²»ç–—è½¬ç§»æ€§ä¹³è…ºç™Œçš„â…¡æœŸä¸´åºŠç ”ç©¶ç»“æœæ˜¾ç¤ºï¼Œè¯¥ç»„åˆåœ¨æ— è¿›å±•ç”Ÿå­˜æœŸã€æ€»ç”Ÿå­˜æœŸã€å®¢è§‚ç¼“è§£ç‡ç­‰æŒ‡æ ‡ä¸­å‡æœªæ˜¾ç¤ºæœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚ä½†æ˜¯ï¼ŒJungç­‰[39]å¼€å±•çš„æ™šæœŸå®ä½“ç˜¤çš„â… æœŸä¸´åºŠç ”ç©¶ç»“æœæ˜¾ç¤ºï¼Œatezolizumabè”åˆnavoximodæ²»ç–—å¯¹äºæ™šæœŸå®ä½“ç˜¤æ‚£è€…å…·æœ‰è‰¯å¥½çš„å®‰å…¨æ€§å’Œå¯è€å—æ€§ã€‚å°½ç®¡è¯•éªŒä¸­è§‚å¯Ÿåˆ°äº†æŠ—è‚¿ç˜¤æ´»æ€§ï¼Œä½†æ²¡æœ‰æ˜ç¡®è¯æ®è¡¨æ˜atezolizumabè”åˆnavoximodæ˜¯æœ‰ç›Šäºæ²»ç–—çš„ã€‚navoximodä»æ˜¯ä¸€ç§å…·æœ‰æ½œåŠ›çš„æ–°å‹å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ã€‚</p><p><strong>2.4â€ƒBMS-986205â€ƒ</strong>BMS-986205æ˜¯ç”±Bristol-Myers Squibbå…¬å¸æŠ•èµ„ç ”å‘çš„ä¸€ç§ç‹¬ç‰¹çš„IDOæŠ‘åˆ¶å‰‚ï¼ˆç»“æ„å¼è§å›¾5ï¼‰ã€‚ä½“å¤–è¯•éªŒæ•°æ®è¡¨æ˜ï¼ŒBMS-986205å¯¹IDOçš„æŠ‘åˆ¶æ•ˆæœå¥½[40,41]ã€‚NCT02658890ç ”ç©¶æ¯”è¾ƒBMS-986205å•è¯ä¸BMS-986205è”åˆçº³æ­¦åˆ©å°¤å•æŠ—æ²»ç–—é»‘è‰²ç´ ç˜¤çš„â… /â…¡æœŸç ”ç©¶ã€‚ä¸€ä»½ä¸­æœŸæŠ¥å‘ŠæŒ‡å‡ºè¯¥åŒ–åˆç‰©åœ¨æ‚£è€…ä¸­è€å—æ€§è‰¯å¥½ã€‚åœ¨å…¶ä»–ç±»å‹æ™šæœŸç™Œç—‡æ‚£è€…ä¸­ä¹Ÿè¿›è¡Œäº†ç›¸åŒç»„åˆçš„ç ”ç©¶ï¼ˆNCT03192943ï¼‰ï¼Œå¹¶äº2018å¹´å®Œæˆï¼Œç»“æœæ˜¾ç¤ºBMS-986205å®‰å…¨æ€§å’Œè€å—æ€§å‡è‰¯å¥½ã€‚ç›®å‰å°†BMS-986205è”åˆçº³æ­¦åˆ©å°¤å•æŠ—æ²»ç–—è‚ç™Œçš„ä¸´åºŠè¯•éªŒæ­£åœ¨æ‹›å‹Ÿä¸­ï¼ˆNCT03695250ï¼‰[42]ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/17cb179b62d1445a96805d35a68b6e0a><p class=pgc-img-caption></p></div><p><br></p><p>2.5â€ƒPF-06840003â€ƒPF-06840003æ˜¯ç”±è¾‰ç‘å…¬å¸ç ”å‘çš„éç«äº‰æ€§ã€éè¡€çº¢è›‹ç™½ç»“åˆçš„IDOæŠ‘åˆ¶å‰‚ï¼Œä¹Ÿæ˜¯ä¸€ç§ç”Ÿç‰©åˆ©ç”¨åº¦è¾ƒé«˜çš„é€‰æ‹©æ€§IDOæŠ‘åˆ¶å‰‚ï¼ˆç»“æ„å¼è§å›¾6ï¼‰ã€‚PF-06840003å¯ä»¥é€šè¿‡äººä½“è¡€-è„‘è„Šæ¶²å±éšœï¼Œå› æ­¤å¯¹è‚¿ç˜¤è„‘è½¬ç§»å¯èƒ½æœ‰å¹²æ‰°å’ŒæŠ‘åˆ¶ä½œç”¨ã€‚åœ¨åŸºç¡€ç ”ç©¶ä¸­ï¼ŒPF-06840003å¢å¼ºäº†æŠ—è‚¿ç˜¤ä½œç”¨ã€‚ç›®å‰ï¼ŒPF-06840003å·²åœ¨æ¶æ€§èƒ¶è´¨ç˜¤æ‚£è€…ä¸­å¼€å±•äº†â… æœŸä¸´åºŠè¯•éªŒï¼ˆNCT02764151ï¼‰[43]ã€‚</p><p><br></p><div class=pgc-img><img alt=æœ‰æ•ˆæŠ‘åˆ¶è¿™ç§é…¶çš„æ´»æ€§å¯å¯åŠ¨ä½“å†…æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼ç ”ç©¶ç°çŠ¶åœ¨è¿™é‡Œ onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/cbbac17301454a43956784e27ec740f0><p class=pgc-img-caption></p></div><p><br></p><p><strong>2.6â€ƒHTI-1090â€ƒ</strong>ä¹Ÿç§°ä¸ºSHR9146ï¼Œæ˜¯ä¸€ç§æ–°å‹ä¸”é«˜æ•ˆçš„å°åˆ†å­IDO1/TDOåŒé‡æŠ‘åˆ¶å‰‚ï¼Œå…¶ç»“æ„ä¸epacadostatç±»ä¼¼ï¼Œå…·æœ‰è‰¯å¥½çš„å£æœç”Ÿç‰©åˆ©ç”¨åº¦å’Œå®‰å…¨æ€§ï¼Œä¸€é¡¹å…³äºHTI-1090æ²»ç–—æ™šæœŸå®ä½“ç˜¤çš„â… æœŸä¸´åºŠè¯•éªŒï¼ˆNCT03208959ï¼‰å·²åœ¨2019å¹´1æœˆå®Œæˆã€‚</p><h1 class=pgc-h-arrow-right>3â€ƒå±•æœ›</h1><p>å½“å‰ä»æœ‰å¤šç§IDOæŠ‘åˆ¶å‰‚æ­£åœ¨ç ”å‘ä¸­ã€‚å¦å¤–ï¼Œåœ¨è‚¿ç˜¤å…ç–«ç–—æ³•ä¸­å°†çº³ç±³æŠ€æœ¯ä¸IDOæŠ‘åˆ¶å‰‚ç›¸èåˆï¼Œä»è€Œå®ç°æ›´ç²¾å‡†çš„é¶å‘æ²»ç–—æ—¢å…·æœ‰å‰æ™¯ä¹Ÿå…·æœ‰æŒ‘æˆ˜æ€§[44,45]ã€‚IDOåœ¨è¯±å¯¼å®¿ä¸»è‚¿ç˜¤å…ç–«è€å—ååº”ä¸­çš„æœºåˆ¶å¤æ‚å¤šæ ·ï¼Œå¾ˆå¤šæœ‰å…³IDOè°ƒæ§è‚¿ç˜¤å…ç–«çš„ç†è®ºå’ŒçŒœæµ‹ä»éœ€è¦è¿›ä¸€æ­¥æ¢ç´¢ã€ç ”ç©¶ä¸è¯å®ã€‚æ­¤å¤–ï¼Œå…³äºIDOæŠ‘åˆ¶å‰‚çš„ç ”å‘è™½ç„¶å–å¾—äº†å¾ˆå¤§è¿›å±•ï¼Œä½†IDOæŠ‘åˆ¶å‰‚ä¸ä¼ ç»ŸåŒ–ç–—è¯ç‰©ã€é¶å‘è¯ç‰©ä»¥åŠå…ç–«ç–—æ³•ã€æ”¾ç–—è¿›è¡Œè”åˆæ²»ç–—çš„æ•ˆæœä»éœ€éªŒè¯ã€‚</p><p><br></p><p>å‚è€ƒæ–‡çŒ®</p><p>[1] Munn DH, Mellor AL. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance[J]. Trends Immunol, 2016, 37(3):193-207.</p><p>[2] King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxÂ­ygenase[J]. Int J Biochem Cell Biol, 2007, 39(12):2167-2172.</p><p>[3] Huang GL, Tao A, Miyazaki T, et al. PEG-Poly(1-Methyl-l-Tryptophan)-Based Polymeric Micelles as Enzymatically ActiÂ­vÂ­ated Inhibitors of Indoleamine 2,3-Dioxygenase[J]. NanoÂ­materials (Basel), 2019, 9(5).pii:E719.</p><p>[4] Najfeld V, Menninger J, Muhleman D, et al. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12-->p11 by fluorescent in situ hybridization[J]. Cytogenet Cell Genet, 1993, 64(3-4):231-232.</p><p>[5] Theate I, van Baren N, Pilotte L, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues[J]. Cancer Immunol Res, 2015, 3(2):161-172.</p><p>[6] Dai X, Zhu BT. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions[J]. J Histochem Cytochem, 2010, 58(1):17-28.</p><p>[7] Tang D, Yue L, Yao R, et al. P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer[J]. OncoÂ­target, 2017, 8(33):54548-54557.</p><p>[8] Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells[J]. Sci Transl Med, 2013, 5(200): 200ra116.</p><p>[9] Carvajal-Hausdorf DE, Mani N, Velcheti V, et al. Objective measÂ­Â­uÂ­rÂ­ement and clinical significance of IDO1 protein in hormÂ­one receptor-positive breast cancer[J]. J Immunother Cancer, 2017, 5(1):81.</p><p>[10] å§œè‰³ä¸½ï¼Œæ–¹è‰³ç§‹ï¼ŒèŠ¦å°å•ï¼Œç­‰ï¼å²å“šèƒº2,3-åŒåŠ æ°§é…¶åœ¨è‰¯ã€æ¶æ€§åµå·¢è‚¿ç˜¤ä¸­çš„è¡¨è¾¾åŠä¸´åºŠæ„ä¹‰[J]ï¼ä¸­å›½å¦‡å¹¼ä¿å¥ï¼Œ2014ï¼Œ29ï¼ˆ36ï¼‰ï¼š6106-6108ï¼</p><p>[11] Wardhani LO, Matsushita M, Iwasaki T, et al. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma[J]. Hum Pathol, 2019, 84:52-61.</p><p>[12] Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells[J]. Clin Cancer Res, 2006, 12(4):1144-1151.</p><p>[13] Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy[J]. Eur J Cancer, 2017, 76:167-182.</p><p>[14] Selvan SR, Dowling JP, Kelly WK, et al. Indoleamine 2,3-dioxy-</p><p>Â­genase (IDO): Biology and Target in Cancer ImmunotÂ­heraÂ­pies[J]. Curr Cancer Drug Targets, 2016, 16(9):755-764.</p><p>[15] Moon YW, Hajjar J, Hwu P, et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer[J]. J Immunother Cancer, 2015, 3:51.</p><p>[16] Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2008, 134(11):1247-1253.</p><p>[17] Fox E, Oliver T, Rowe M, et al. Indoximod: An ImmunomÂ­etabolic Adjuvant That Empowers T Cell Activity in Cancer[J]. Front Oncol, 2018, 8:370.</p><p>[18] Metz R, Rust S, Duhadaway JB, et al. IDO inhibits a tryptoÂ­phan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan[J]. OncoiÂ­mmunology, 2012, 1(9):1460-1468.</p><p>[19] Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemoÂ­therapy[J]. Nat Med, 2005, 11(3):312-319.</p><p>[20] ç‹ç¿ å¨Ÿï¼Œå°šæ˜ï¼Œé‚µåï¼èŠ³é¦™çƒƒå—ä½“åœ¨è‚¿ç˜¤å‘ç”ŸåŠå…ç–«æ²»ç–—ä¸­çš„ä½œç”¨[J]ï¼ä¸­åè‚¿ç˜¤é˜²æ²»æ‚å¿—ï¼Œ2018ï¼Œ25ï¼ˆ15ï¼‰ï¼š1126-1130ï¼</p><p>[21] Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells[J]. Science, 2010, 329(5997):1345-1348.</p><p>[22] Dons EM, Raimondi G, Cooper DK, et al. Induced regulatory T cells: mechanisms of conversion and suppressive potential[J]. Hum Immunol, 2012, 73(4):328-334.</p><p>[23] Hill M, Tanguy-Royer S, Royer P, et al. IDO expands human CD4+CD25 high regulatory T cells by promoting maturation of LPS-treated dendritic cells[J]. Eur J Immunol, 2007, 37(11): 3054-3062.</p><p>[24] Prendergast GC, Malachowski WP, DuHadaway JB, et al. Discovery of IDO1 Inhibitors: From Bench to Bedside[J]. Cancer Res, 2017, 77(24):6795-6811.</p><p>[25] å‘¨æ˜ çº¢ï¼å°åˆ†å­IDO-1æŠ‘åˆ¶å‰‚ç ”ç©¶è¿›å±•[J]ï¼ä¸­å›½æŠ—ç”Ÿç´ æ‚å¿—ï¼Œ2016ï¼Œ41ï¼ˆ10ï¼‰ï¼š721-726ï¼</p><p>[26] Soliman HH, Jackson E, Neuger T, et al. A first in man phase â…  trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors[J]. Oncotarget, 2014, 5(18):8136-8146.</p><p>[27] Soliman HH, Minton SE, Han HS, et al. A phase â…  study of indoxÂ­imod in patients with advanced malignancies[J]. OncotÂ­arget, 2016, 7(16):22928-22938.</p><p>[28] ä»£éœ–éœ–ï¼Œæå†¬å†¬ï¼å°åˆ†å­è‚¿ç˜¤å…ç–«æ²»ç–—è¯ç‰©çš„ä¸´åºŠç ”ç©¶è¿›å±•[J]ï¼ä¸­å›½æ–°è¯ä¸ä¸´åºŠæ‚å¿—ï¼Œ2019ï¼Œ30ï¼ˆ8ï¼‰ï¼š455-463ï¼</p><p>[29] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5):411-422.</p><p>[30] Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity[J]. Blood, 2010, 115(17):3520-3530.</p><p>[31] Yue EW, Sparks R, Polam P, et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology[J]. ACS Med Chem Lett, 2017, 8(5):486-491.</p><p>[32] Beatty GL, O'Dwyer PJ, Clark J, et al. First-in-Human Phase â…  Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies[J]. Clin Cancer Res, 2017, 23(13):3269-3276.</p><p>[33] Long GV, Dummer R, Hamid O, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study[J]. Lancet Oncol, 2019, 20(8):1083-1097.</p><p>[34] Muller AJ, Manfredi MG, Zakharia Y, et al. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond[J]. Semin Immunopathol, 2019, 41(1):41-48.</p><p>[35] No authors listed. Companies Scaling Back IDO1 Inhibitor Trials[J]. Cancer Discov, 2018, 8(7):OF5.</p><p>[36] Mitchell TC, Hamid O, Smith DC, et al. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase â… /â…¡</p><p>Trial (ECHO-202/KEYNOTE-037)[J]. J Clin Oncol, 2018: JCO2018789602.</p><p>[37] Ma S, Suchomel J, Yanez E, et al. Investigation of the absolute bioavaÂ­ilability and human mass balance of navoximod, a novel IDO1 inhibitor[J]. Br J Clin Pharmacol, 2019, 85(8):1751-1760.</p><p>[38] Nayak-Kapoor A, Hao Z, Sadek R, et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors[J]. J Immunother Cancer, 2018, 6(1):61.</p><p>[39] Jung KH, LoRusso P, Burris H, et al. Phase â…  Study of the Indo-Â­</p><p>leÂ­amine 2,3-Dioxygenase 1 (IDO1) Inhibitor NavoxÂ­imod (GDC-0919) Administered with PD-L1 Inhibitor (AtezoÂ­lizumab) in Advanced Solid Tumors[J]. Clin Cancer Res, 2019, 25(11):3220-3228.</p><p>[40] Pham KN, Yeh SR. Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1[J]. J Am Chem Soc, 2018, 140(44):14538-14541.</p><p>[41] Richards T, Brin E. Cell based functional assays for IDO1 inhibitor screening and characterization[J]. Oncotarget, 2018, 9(56):30814-30820.</p><p>[42] Cheong JE, Ekkati A, Sun L. A patent review of IDO1 inhibÂ­itors for cancer[J]. Expert Opin Ther Pat, 2018, 28(4):317-330.</p><p>[43] Gomes B, Driessens G, Bartlett D, et al. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy[J]. Mol Cancer Ther, 2018, 17(12):2530-2542.</p><p>[44] Zulfiqar B, Mahroo A, Nasir K, et al. Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors[J]. Oncol Targets Ther, 2017, 10:463-476.</p><p>[45] Feng B, Zhou F, Hou B, et al. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment[J]. Adv Mater, 2018, 30(38):e1803001.</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'è¿™ç§','å¯åŠ¨ä½“','æŠ—è‚¿ç˜¤'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=æœç´¢>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>ğŸ”</button></form></section><section class=widget><h3 class=widget-title>æœ€æ–°æ–‡ç«  âš¡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>å…¶ä»–</h3><ul class=widget-list><li><a href=TOS.html>ä½¿ç”¨æ¢æ¬¾</a></li><li><a href=CommentPolicy.html>ç•™è¨€æ”¿ç­–</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>è¯çµ¡æˆ‘å€‘</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>æå®¢å¿«è¨Š</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>